Skip to main content
MJH Life Sciences
  • Login
  • Register
  • Login
  • Register
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences
MJH Life Sciences

SUBSCRIBE: Print / eNewsletter

Pembrolizumab Gets New Indications in Advanced Cancer

  • Ian Ingram
May 19, 2017
  • Bladder Cancer, Genitourinary Cancers
Pembrolizumab was approved in the first- and second-line settings

The US Food and Drug Administration (FDA) has granted pembrolizumab (Keytruda) regular approval for the second-line treatment of locally advanced or metastatic urothelial carcinoma patients whose disease has progressed during or after platinum-containing chemotherapy, either in the neoadjuvant or adjuvant setting, as well as accelerated approval for the first-line treatment of cisplatin-ineligible patients.

“Keytruda is now available for use as a first-line treatment option for patients with advanced urothelial bladder cancer who are not eligible for the standard of care, cisplatin-based chemotherapy,” said study investigator Dean F. Bajorin, MD, medical oncologist at Memorial Sloan Kettering Cancer Center in New York, in a press release. “With the second-line indication, Keytruda also provides a new option for patients with advanced urothelial bladder cancer—and is the only anti–PD-1 therapy to show an overall survival benefit vs chemotherapy in a phase III study.”

Results from the multicenter KEYNOTE-045 trial led to the pembrolizumab approval in the second-line setting. The trial randomized 542 patients with locally advanced or metastatic urothelial carcinoma, whose disease had progressed on or after platinum-containing chemotherapy, to either pembrolizumab or chemotherapy. Every 3 weeks, patients received either 200-mg pembrolizumab (n = 270) or investigator’s choice of chemotherapy (n = 272; 75-mg/m2 docetaxel, 175-mg/m2 paclitaxel, or 320-mg/m2 vinflunine).

Patients on pembrolizumab had an improved overall response rate (21% vs 11%; P = .002). Median overall survival was also improved with pembrolizumab, at 10.3 months vs 7.4 months in those on chemotherapy for a hazard ratio (HR) of 0.73 (95% CI, 0.59–0.91; P = .004).

Results from the KEYNOTE-052 trial led to the pembrolizumab approval in the first-line setting. This open-label trial included 370 cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma. Pembrolizumab was administered every 3 weeks at a 200-mg dose in all patients. Overall response rate was 28.6% (95% CI, 24%–34%) with a median follow-up of 7.8 months; the median response duration was not reached (1.4–17.8 months).

Adverse events (AEs) led to treatment discontinuation in 8% of patients In KEYNOTE-045 and 11% of patients in KEYNOTE-052, with pneumonitis (1.9%) being the most common reason. AEs led to treatment interruption in 20% of patients, with diarrhea and urinary tract infection (1.5% each) and colitis (1.1%) being the most common reasons.

The most common AEs (20% or greater) in pembrolizumab-treated vs chemotherapy-treated patients were decreased appetite (21% vs 21%), fatigue (38% vs 56%), musculoskeletal pain (32% vs 27%), nausea (21% vs 29%), pruritus (23% vs 6%), and rash (20% vs 13%). Serious AEs occurred in 39% of pembrolizumab-treated patients, with anemia, pneumonia, pneumonitis, and urinary tract infection being the most common (all 2% or greater).

Related Articles

Resource Topics rightRail

  • Resource Topics
  • Partner Content
  • Breast Cancer
  • Acute Myeloid Leukemia
  • HER2-Positive Breast Cancer
  • Videos Breast Cancer
  • Follicular Lymphoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

ONCOLOGY Vol 33 No 11
Nov 21, 2019 Vol 33 No 11
Subscribe
Connect with Us
  • Column 1
    • Home
    • About Us
    • Contact Us
  • Column 2
    • Editorial Info
    • Editorial Board
  • Column 3
    • Advertising Info
    • Reprints
    • Advertising Terms
  • Column 4
    • Terms of Use
    • Privacy Policy
Modern Medicine Network
© UBM 2019, All rights reserved.
Reproduction in whole or in part is prohibited.

We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".